119 related articles for article (PubMed ID: 32359336)
21. Downregulation of glypican-3 expression increases migration, invasion, and tumorigenicity of human ovarian cancer cells.
Liu Y; Zheng D; Liu M; Bai J; Zhou X; Gong B; Lü J; Zhang Y; Huang H; Luo W; Huang G
Tumour Biol; 2015 Sep; 36(10):7997-8006. PubMed ID: 25967456
[TBL] [Abstract][Full Text] [Related]
22. Adipocyte-Induced FABP4 Expression in Ovarian Cancer Cells Promotes Metastasis and Mediates Carboplatin Resistance.
Mukherjee A; Chiang CY; Daifotis HA; Nieman KM; Fahrmann JF; Lastra RR; Romero IL; Fiehn O; Lengyel E
Cancer Res; 2020 Apr; 80(8):1748-1761. PubMed ID: 32054768
[TBL] [Abstract][Full Text] [Related]
23. MKNK2 enhances chemoresistance of ovarian cancer by suppressing autophagy via miR-125b.
Wang J; Da C; Su Y; Song R; Bai Z
Biochem Biophys Res Commun; 2021 Jun; 556():31-38. PubMed ID: 33836345
[TBL] [Abstract][Full Text] [Related]
24. Neurotensin Receptor 1 Antagonist SR48692 Improves Response to Carboplatin by Enhancing Apoptosis and Inhibiting Drug Efflux in Ovarian Cancer.
Liu J; Agopiantz M; Poupon J; Wu Z; Just PA; Borghese B; Ségal-Bendirdjian E; Gauchotte G; Gompel A; Forgez P
Clin Cancer Res; 2017 Nov; 23(21):6516-6528. PubMed ID: 28790113
[No Abstract] [Full Text] [Related]
25. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
Chan KK; Wong OG; Wong ES; Chan KK; Ip PP; Tse KY; Cheung AN
Int J Cancer; 2018 Sep; 143(6):1456-1469. PubMed ID: 29663364
[TBL] [Abstract][Full Text] [Related]
26. Extracellular vesicles of Bifidobacterium longum reverse the acquired carboplatin resistance in ovarian cancer cells via p53 phosphorylation on Ser15.
Fan YL; Jin JX; Zhu J; Ruan HB; Huang JQ
Kaohsiung J Med Sci; 2024 Jun; 40(6):530-541. PubMed ID: 38647095
[TBL] [Abstract][Full Text] [Related]
27. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
[TBL] [Abstract][Full Text] [Related]
28. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy.
Zhang XY; Zhang M; Cong Q; Zhang MX; Zhang MY; Lu YY; Xu CJ
Int J Biochem Cell Biol; 2018 Feb; 95():9-16. PubMed ID: 29247711
[TBL] [Abstract][Full Text] [Related]
29. Knockdown of survivin contributes to antitumor activity in cisplatin-resistant ovarian cancer cells.
Jiang L; Luo RY; Yang J; Cheng YX
Mol Med Rep; 2013 Feb; 7(2):425-30. PubMed ID: 23229441
[TBL] [Abstract][Full Text] [Related]
30. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
[TBL] [Abstract][Full Text] [Related]
31. EZH2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells.
Wen Y; Hou Y; Yi X; Sun S; Guo J; He X; Li T; Cai J; Wang Z
Theranostics; 2021; 11(4):1795-1813. PubMed ID: 33408782
[No Abstract] [Full Text] [Related]
32. Knockdown of eIF4E suppresses cell proliferation, invasion and enhances cisplatin cytotoxicity in human ovarian cancer cells.
Wan J; Shi F; Xu Z; Zhao M
Int J Oncol; 2015 Dec; 47(6):2217-25. PubMed ID: 26498997
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo.
Hu S; Yu L; Li Z; Shen Y; Wang J; Cai J; Xiao L; Wang Z
Cancer Biol Ther; 2010 Oct; 10(8):788-95. PubMed ID: 20686362
[TBL] [Abstract][Full Text] [Related]
34. miR-146b promotes cell proliferation and increases chemosensitivity, but attenuates cell migration and invasion via FBXL10 in ovarian cancer.
Yan M; Yang X; Shen R; Wu C; Wang H; Ye Q; Yang P; Zhang L; Chen M; Wan B; Zhang Q; Xia S; Lu X; Shao G; Zhou X; Yu J; Shao Q
Cell Death Dis; 2018 Nov; 9(11):1123. PubMed ID: 30409964
[TBL] [Abstract][Full Text] [Related]
35. E2F8 Induces Cell Proliferation and Invasion through the Epithelial-Mesenchymal Transition and Notch Signaling Pathways in Ovarian Cancer.
Eoh KJ; Kim HJ; Lee JW; Kim LK; Park SA; Kim HS; Kim YT; Koo PJ
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823614
[TBL] [Abstract][Full Text] [Related]
36. FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells.
Choi EJ; Seo EJ; Kim DK; Lee SI; Kwon YW; Jang IH; Kim KH; Suh DS; Kim JH
Oncotarget; 2016 Jan; 7(3):3506-19. PubMed ID: 26654944
[TBL] [Abstract][Full Text] [Related]
37. ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2.
Luo Q; Wu X; Zhang Y; Shu T; Ding F; Chen H; Zhao P; Chang W; Zhu X; Liu Z
Cancer Lett; 2018 Jul; 427():9-17. PubMed ID: 29660381
[TBL] [Abstract][Full Text] [Related]
38. Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer cells to cisplatin through inhibiting the Notch1 signaling pathway.
Bai L; Wang A; Zhang Y; Xu X; Zhang X
Exp Cell Res; 2018 May; 366(2):161-171. PubMed ID: 29548748
[TBL] [Abstract][Full Text] [Related]
39. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
Tang X; Lu M; Li C; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
[TBL] [Abstract][Full Text] [Related]
40. MCT1 promotes the cisplatin-resistance by antagonizing Fas in epithelial ovarian cancer.
Yan C; Yang F; Zhou C; Chen X; Han X; Liu X; Ma H; Zheng W
Int J Clin Exp Pathol; 2015; 8(3):2710-8. PubMed ID: 26045776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
